Literature DB >> 1868679

A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers.

A L van Steveninck1, H C Schoemaker, M S Pieters, R Kroon, D D Breimer, A F Cohen.   

Abstract

The effects of single oral doses of 5, 10, and 20 mg temazepam were evaluated with the adaptive tracking test, analysis of smooth-pursuit and saccadic eye movements, and visual analog lines in a placebo-controlled, double-blind, crossover experiment with 12 healthy volunteers. Pharmacodynamic testing was performed until 10 hours and pharmacokinetics were evaluated until 24 hours. Temazepam, 20 mg, caused effects in all tests, with peak effects occurring at 30 minutes. The 10 mg dose caused effects on saccadic eye movements and subjective scores of alertness, whereas 5 mg temazepam was detected only by analysis of saccadic eye movements. Linear relationships between plasma concentrations and effects were found in nine subjects for saccadic peak velocity and eight subjects for subjective scores of alertness. The results of this study demonstrate manifest differences in the sensitivities of performance tests and stress the importance of validation of methods when effects of drugs on human performance are studied.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868679     DOI: 10.1038/clpt.1991.122

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  36 in total

Review 1.  Biomarkers for the effects of antipsychotic drugs in healthy volunteers.

Authors:  S J de Visser; J van der Post; M S Pieters; A F Cohen; J M van Gerven
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

2.  Estimating potency for the Emax-model without attaining maximal effects.

Authors:  R C Schoemaker; J M van Gerven; A F Cohen
Journal:  J Pharmacokinet Biopharm       Date:  1998-10

3.  Model-based meta-analysis of the effects of non-selective and α1-selective GABAA receptor agonists in healthy volunteers.

Authors:  Yu-Peng Ren; Ru-Jia Xie; Scott Marshall; Liang Li; Tian-Yan Zhou; Wei Lu
Journal:  Eur J Clin Pharmacol       Date:  2015-08-11       Impact factor: 2.953

4.  Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses.

Authors:  Ricardo Alvarez-Jimenez; Ellen P Hart; Samantha Prins; Marieke de Kam; Joop M A van Gerven; Adam F Cohen; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

5.  The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.

Authors:  J P van der Post; S J de Visser; M L de Kam; M Woelfler; D C Hilt; J Vornov; E S Burak; E Bortey; B S Slusher; T Limsakun; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

6.  Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state.

Authors:  A L van Steveninck; R Gieschke; H C Schoemaker; M S Pieters; J M Kroon; D D Breimer; A F Cohen
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist.

Authors:  Priska Kaufmann; Marion Ort; Georg Golor; Rüdiger Kornberger; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2020-03-06       Impact factor: 4.335

Review 8.  Biomarkers for the effects of benzodiazepines in healthy volunteers.

Authors:  S J de Visser; J P van der Post; P P de Waal; F Cornet; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

9.  The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.

Authors:  Xia Chen; Gabriël Jacobs; Marieke de Kam; Judith Jaeger; Jaakko Lappalainen; Paul Maruff; Mark A Smith; Alan J Cross; Adam Cohen; Joop van Gerven
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

10.  Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.

Authors:  Erik T te Beek; Justin L Hay; Jonathan N Bullman; Clare Burgess; Kimberly J Nahon; Erica S Klaassen; Frank A Gray; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.